Six days after an executive order on mental illness, the FDA gave psilocybin a voucher, not an approval

No psychedelic drug has been approved for marketing in the United States. The Food and Drug Administration says so itself, in a Federal Register notice published on 14 July 2026, which states that neither the issuance of a national priority voucher nor breakthrough therapy designation constitutes a determination of safety or effectiveness.

The order that set the current wave in motion is Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness, signed on 18 April 2026 and published in the Federal Register on 22 April 2026. Its opening section says more than 14 million American adults have a serious mental illness. Section 2 directs the FDA Commissioner to provide national priority vouchers for breakthrough psychedelic drugs and to establish access pathways under the Right to Try Act. Section 3 requires the Advanced Research Projects Agency for Health to allocate at least 50 million US dollars from existing funds to state programmes developing psychedelic treatments. Section 4 requires collaboration between HHS, the FDA and the Department of Veterans Affairs on trials and data sharing. Section 5 directs the Attorney General to initiate and complete a review of Schedule I substances that complete Phase 3 trials for mental health disorders, so that rescheduling can follow if appropriate. The order sets no dated deadlines, requiring action as quickly as practicable.

Six days later, on 24 April 2026, the FDA issued Commissioner's National Priority Vouchers to three psychedelic programmes. The July Federal Register notice describes them as covering psilocybin treatments and methylone for post traumatic stress disorder. The Penn Leonard Davis Institute reports the same three, two psilocybin programmes for severe depression and one for an MDMA metabolite for PTSD, and describes the voucher as compressing review from about ten months to one to two months.

The compression is a target, not a guarantee, and it only starts once an application is filed. Compass Pathways is furthest along. Its pivotal Phase 3 trial, registered as NCT05711940, is titled a multicentre, randomised, double blind, controlled study of two administrations of COMP360 in participants with treatment resistant depression. The registry lists 572 participants, a status of active and not recruiting, a start date of 14 February 2023 and a primary completion date of 13 November 2025, with the primary endpoint being change in the Montgomery Asberg Depression Rating Scale at week 6 for 25 mg against 1 mg. An earlier trial, NCT05624268, with 258 participants, is recorded as completed.

The trade publication Psychedelic Beacon, tracking the programme, reports a 3.6 point MADRS advantage over placebo in the 258 patient study and a 3.8 point advantage in the larger one, which it describes as enrolling 581 patients, a figure higher than the 572 the registry records. It reports 26 week durability results released on 7 July 2026, with nearly 30 per cent of week six responders reaching remission after retreatment, and a rolling new drug application that Compass aims to complete in the fourth quarter of 2026, with a possible decision between the fourth quarter of 2026 and the first quarter of 2027. Those timings are the company's own projections. Usona Institute holds a separate breakthrough designation for psilocybin in major depressive disorder, a broader indication, and has not reported topline Phase 3 results.

Academics at the University of Pennsylvania have been blunter than the announcements. Holly Fernandez Lynch, a senior fellow at the Leonard Davis Institute, called the executive order primarily symbolic and said, of the direction given to the regulator, "It's a pretty egregious step for the White House to direct the FDA with regard to specific products." Heath D. Schmidt of Penn's schools of nursing and medicine said, "We should learn to walk before we run." Margaret Lowenstein noted the limitations of the existing evidence.

The government's own posture is preparatory rather than triumphant. A Health Resources and Services Administration request for information published on 14 July 2026, with comments due by 13 August 2026, asks about workforce training, delivery models in ambulatory clinics serving underserved communities and the role of technology, and refers throughout to potential future FDA approved psychedelic drugs. The FDA has scheduled a public hearing for 14 September 2026 at White Oak in Silver Spring, with registration closing on 21 August 2026 and written comments accepted until 5 October 2026. The agency states that scheduling, legalisation and the merits of specific pending applications are outside the hearing's scope.

What is not known is when a completed application will actually be filed, whether the one to two month review target survives contact with a real submission, and whether the Attorney General's rescheduling review has begun.